Von den Profis lernen. Beim Kostensieger handeln.

Eröffne jetzt dein Depot bei unserem Broker finanzen.net ZERO – und lies 3 Monate kostenfrei das Fachmagazin der Börsenexperten, die NVIDIA schon vor einem Jahrzehnt auf der Kaufliste hatten.

Handle deine Aktien beim Kostensieger der Stiftung Warentest (12/2025)

Entdecke mit dem aktien-Magazin chancenreiche Titel, bevor der Mainstream sie kennt (Wert: 147 €)

Sichere dir zusätzlich 50 € Neukundenbonus direkt auf dein Cash-Konto

Zealand Pharma A-S Aktie

40,13 EUR +0,91 EUR +2,32 %

13:17:50

STU

37,10 CHF +0,44 CHF +1,19 %

13:19:02

BRX

Zealand Pharma A-S jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.2,65 Mrd. EUR

KGV5,09Div. Rendite0,00%

WKNA0YJW7

ISINDK0060257814

SymbolZLDPF

Zealand Pharma A-S Aktien News

Sortieren:Datum Meistgelesen

06.06.25GlobeNewswireZealand Pharma increases its share capital as a result of the exercise of employee warrants

27.05.25GlobeNewswireTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

09.05.25GlobeNewswireZealand Pharma announces closing of collaboration and license agreement with Roche

WerbungZealand Pharma A-S-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

08.05.25GlobeNewswireZealand Pharma Announces Financial Results for the First Three Months of 2025

19.04.25GlobeNewswireTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

19.04.25GlobeNewswireZealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025

31.03.25GlobeNewswireTotal number of shares and voting rights in Zealand Pharma as of March 31, 2025

27.03.25GlobeNewswireResolutions from Zealand Pharma's Annual General Meeting 2025

25.03.25GlobeNewswireZealand Pharma major shareholder announcement: Van Herk Investments B.V.

20.03.25GlobeNewswireZealand Pharma increases its share capital as a result of the exercise of employee warrants

12.03.25GlobeNewswireZealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity

20.02.25GlobeNewswireZealand Pharma convenes its Annual General Meeting 2025

20.02.25GlobeNewswireZealand Pharma Announces Financial Results for the Full Year 2024

13.01.25GlobeNewswireTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

25.12.24GlobeNewswireTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

25.12.24GlobeNewswireZealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

19.12.24GlobeNewswireU.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome

11.11.24GlobeNewswireTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

07.11.24GlobeNewswireZealand Pharma Announces Financial Results for the First Nine Months of 2024

09.10.24GlobeNewswireZealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism

08.10.24GlobeNewswireZealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide

30.09.24GlobeNewswireTotal number of shares and voting rights in Zealand Pharma A/S on September 30, 2024

12.09.24GlobeNewswireZealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

09.09.24GlobeNewswireZealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide

30.08.24GlobeNewswireTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

30.08.24GlobeNewswireTotal number of shares and voting rights in Zealand Pharma on August 30, 2024

22.08.24GlobeNewswireZealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

16.08.24GlobeNewswireZealand Pharma major shareholder announcement: Bank of America Corporation

15.08.24GlobeNewswireZealand Pharma Announces Financial Results for the First Half of 2024

28.06.24GlobeNewswireZealand Pharma major shareholder announcement: Van Herk Investments

28.06.24GlobeNewswireTotal number of shares and voting rights in Zealand Pharma at June 28, 2024

28.06.24GlobeNewswireZealand Pharma completes registration of capital increase

26.06.24GlobeNewswireZealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion

25.06.24GlobeNewswireZealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion

25.06.24GlobeNewswireZealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion

20.06.24GlobeNewswireZealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide

13.06.24GlobeNewswireZealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

07.06.24GlobeNewswireZealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis

06.06.24GlobeNewswireZealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL

29.05.24GlobeNewswireZealand Pharma major shareholder announcement: Polar Capital

Zealand Pharma A-S News

Zealand Pharma A-S News: auf dieser Seite finden Sie alle Zealand Pharma A-S News und Nachrichten zur Zealand Pharma A-S Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Zealand Pharma A-S News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Zealand Pharma A-S News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.